Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 15/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 10/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660022 | 1.00 | PRKCZ (1.00) | PRKCZPRKD2ROCK2ROCK1CSNK2A1 | |
| SCHEMBL661175 | 1.00 | PRKCZ (1.00) | PRKCZPRKD2ROCK2ROCK1CSNK2A1 | |
| Hydrochloric Acid SCHEMBL5662171 | 0.99 | PRKCZ (0.97) | PRKCZPRKD2ROCK2ROCK1CSNK2A1 | |
| SCHEMBL435269 | 0.92 | PRKCZ (0.85) | PRKCZPRKD2ROCK2ROCK1 | |
| SCHEMBL528095 | 0.92 | PRKCZ (0.85) | PRKCZPRKD2ROCK2ROCK1 | |
| SCHEMBL435270 | 0.92 | PRKCZ (0.85) | PRKCZPRKD2ROCK2ROCK1 | |
| Bicarbonate SCHEMBL2112761 | 0.86 | PRKCZ (0.76) | PRKCZPRKD2ROCK2ROCK1CSNK2A1 | |
| Bicarbonate SCHEMBL27827793 | 0.86 | PRKCZ (0.76) | PRKCZPRKD2ROCK2ROCK1CSNK2A1 | |
| SCHEMBL5664354 | 0.84 | ROCK2 (0.74) | PRKCZROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL29862866 | 0.83 | ROCK2 (0.72) | PRKCZROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914590-B1 | NOVEL ROCK INHIBITORS | PH PHARMA CO LTD (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9394286-B2 | Rock inhibitors | AMAKEM NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | AMAKEM NV (BE) | 2015-10-22 | — | — | US | disclosed |
| US-9073905-B2 | Rock inhibitors | AMAKEM NV (BE) | 2015-07-07 | — | — | US | disclosed |
| WO-2014068035-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-05-08 | — | — | WO | disclosed |
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-103249305-A | Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms | INSPIRE PHARMACEUTICALS INC | 2013-08-14 | — | — | CN | disclosed |
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| CN-101583361-A | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC (US) | 2009-11-18 | — | — | CN | disclosed |
| EP-2099457-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | PRKCZ 189/4885PRKD2 102/4885ROCK2 2/4885 |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | ROCK1, ROCK2, CIT | PRKCZ 83/4885PRKD2 63/4885ROCK2 2/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | PRKCZ 192/4885PRKD2 173/4885ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.